<DOC>
	<DOCNO>NCT00915083</DOCNO>
	<brief_summary>The purpose study determine whether amrubicin safe effective treatment patient advance solid tumor . The study ass pharmacokinetics amrubicin effect heart .</brief_summary>
	<brief_title>A Phase I Study Assess Safety , Pharmacokinetics , Potential Effects Amrubicin QT/QTc Interval Cancer Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Patients meet follow criterion consider enrollment study : 1 . Males female , age 1865 year ; 2 . Histological cytological diagnosis solid malignancy acceptable standard therapy exist approved standard therapy fail ; 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; 4 . Life expectancy great 3 month ; 5 . Nonsmoker smoke use tobacco product least 3 month screen visit agree abstain smoking/using tobacco product throughout formal study End Study visit ; 6 . Capable give informed consent , sign informed consent form , willing comply schedule visit , dose administration , study procedure ; 7 . Women childbearing potential may participate , provide negative serum pregnancy test ( βHCG ) screening , negative urine pregnancy test prior dose Day 1 cycle ; 8 . Males females childbearing potential must agree use least 2 effective contraceptive method least 28 day follow last dose study drug ; 9 . Serum potassium , magnesium correct calcium within institutional normal range screening ; 10 . Adequate organ function include follow : Adequate bone marrow reserve : absolute neutrophil count ( segmented band ) ( ANC ) ≥1.5 x 109/L , platelet count ≥100 x 109/L , hemoglobin ≥90 g/L , Hepatic : bilirubin ≤1.5 x upper limit normal ( ULN ) , ALT AST ≤2.0 x ULN , Renal : serum creatinine ≤1.5 x ULN calculate creatinine clearance &gt; 80 mL/min . Patients meet follow criterion exclude study : 1 . Hypersensitivity amrubicin related compound ; 2 . Radiotherapy curative intent primary disease complex ≤ 28 day first dose ; cranial radiotherapy ≤ 21 day first dose ; radiotherapy area ≤ 7 day first dose amrubicin ; 3 . History presence clinically significant abnormal 12lead ECG triplicate ECGs mean QT interval correct heart rate ( HR ) use Fridericia 's method ( QTcF ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) , PR interval &gt; 240 msec QRS interval &gt; 110 msec ( within 3 month screen visit ) ; 4 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % ; 5 . Recent history ( within 3 month screen visit ) pericarditis pericardial effusion ; 6 . History within 6 month screen visit one following : cardiac disease include congenital longQT syndrome , angina , congestive heart failure , myocardial ischemia infarction , myocarditis , chest pain dyspnea exertion cardiac origin , , idiopathic hypertrophic cardiomyopathy , sarcoidosis , syncope , epilepsy , clinically significant cardiac disease ; 7 . Family history long QT syndrome ; 8 . Use implantable pacemaker implantable cardioverter defibrillator ; 9 . Clinically significant bradycardia ( &lt; 50 beat per minute ) ; 10 . Systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 100 mmHg ; 11 . Previous treatment investigational agent anticancer therapy within 4 week prior 'offdrug ' visit ; 12 . Previous treatment anticancer therapy fully recover ( Common Terminology Criteria Adverse Event [ CTCAE ] Grade 1 , except alopecia ) toxic effect treatment ; 13 . Treatment medication know produce QT prolongation enzymeinducing anticonvulsant , nonprescription medication include topical medication , vitamin , mineral , herbs dietary supplements/remedies ( e.g. , Saint John 's Wort Milk Thistle ) least 7 day start offdrug visit ; 14 . Previous treatment anthracycline ; 15 . Any condition would put patient undue risk discomfort result adherence study procedure ; 16 . Women pregnant nursing ; 17 . Uncontrolled intercurrent illness myelosuppression , renal impairment , hepatic impairment , infection uncontrolled diabetes ; 18 . Symptomatic central nervous system metastasis . Patients asymptomatic brain metastasis allow . The patient must stable ≥ 2 week radiotherapy , patient corticosteroid , dose corticosteroid must stable ≥ 2 week prior first dose study treatment , process taper ; 19 . Suspected , diffuse idiopathic interstitial lung disease pulmonary fibrosis relate prior treatment ; 20 . History seropositive HIV patient receive immunosuppressive myelosuppressive medication would , opinion investigator , increase risk serious neutropenic complication ; 21 . Positive urine drug screen undeclared concomitant medication and/or illegal drug use screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>